Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
DVAX Stock Forecast 2026-2027
$15.50
Current Price
$1.82B
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to DVAX Price Targets
+3.2%
To High Target of $16.00
+3.2%
To Median Target of $16.00
+3.2%
To Low Target of $16.00
DVAX Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+50.3%
1 Year Change
+0.8%
Year-to-Date Change
-1.5%
From 52W High of $15.73
+68.5%
From 52W Low of $9.20
📊 TOP ANALYST CALLS
Did DVAX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Dynavax is one of their latest high-conviction picks.
Latest DVAX Stock Price Targets & Analyst Predictions
Based on our analysis of 10 Wall Street analysts, DVAX has a bullish consensus with a median price target of $16.00 (ranging from $16.00 to $16.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $15.50, the median forecast implies a 3.2% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DVAX Analyst Ratings
1
Buy
0
Hold
0
Sell
DVAX Price Target Range
Low
$16.00
Average
$16.00
High
$16.00
Current: $15.50
Latest DVAX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DVAX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 24, 2025 | William Blair | Matt Phipps | Market Perform | Downgrade | $N/A |
| Aug 22, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Reiterates | $32.00 |
| Aug 8, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Maintains | $32.00 |
| May 7, 2025 | JMP Securities | Roy Buchanan | Market Outperform | Maintains | $31.00 |
| Apr 17, 2025 | Goldman Sachs | Paul Choi | Sell | Maintains | $10.00 |
| Feb 21, 2025 | Citizens Capital Markets | Jason Butler | Market Outperform | Maintains | $33.00 |
| Feb 21, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $31.00 |
| Feb 11, 2025 | Goldman Sachs | Paul Choi | Sell | Downgrade | $12.00 |
| Jan 14, 2025 | HC Wainwright & Co. | Edward White | Buy | Maintains | $31.00 |
| Nov 8, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $29.00 |
| Oct 15, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $29.00 |
| Aug 8, 2024 | Goldman Sachs | Paul Choi | Neutral | Maintains | $15.00 |
| Aug 7, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $29.00 |
| Jun 28, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $29.00 |
| May 14, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $29.00 |
| May 9, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $29.00 |
| Feb 1, 2024 | Goldman Sachs | Paul Choi | Neutral | Initiates | $20.00 |
| Nov 3, 2023 | HC Wainwright & Co. | Edward White | Buy | Maintains | $28.00 |
| Nov 3, 2023 | JMP Securities | Roy Buchanan | Market Outperform | Maintains | $27.00 |
| Aug 4, 2023 | JMP Securities | Roy Buchanan | Outperform | Maintains | $25.00 |
Dynavax Technologies Corporation (DVAX) Competitors
The following stocks are similar to Dynavax based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Dynavax Technologies Corporation (DVAX) Financial Data
Dynavax Technologies Corporation has a market capitalization of $1.82B with a P/E ratio of 54.6x. The company generates $330.51M in trailing twelve-month revenue with a -13.1% profit margin.
Revenue growth is +17.7% quarter-over-quarter, while maintaining an operating margin of +24.8% and return on equity of -7.1%.
Valuation Metrics
Market Cap
$1.82B
Enterprise Value
$1.46B
P/E Ratio
54.6x
PEG Ratio
0.7x
Price/Sales
5.5x
Growth & Margins
Revenue Growth (YoY)
+17.7%
Gross Margin
+84.8%
Operating Margin
+24.8%
Net Margin
-13.1%
EPS Growth
+53.0%
Financial Health
Cash/Price Ratio
+35.6%
Current Ratio
7.6x
Debt/Equity
54.1x
ROE
-7.1%
ROA
+1.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Dynavax Technologies Corporation (DVAX) Business Model
About Dynavax Technologies Corporation
What They Do
Develops vaccines for infectious diseases and cancer.
Business Model
Dynavax Technologies generates revenue by developing and commercializing innovative vaccines, notably its FDA-approved HEPLISAV-B hepatitis B vaccine. The company focuses on utilizing advanced immunology technologies to enhance vaccine efficacy and accessibility, which positions it to capture market share in the biopharmaceutical sector.
Additional Information
Headquartered in Emeryville, California, Dynavax also works on adjuvant technologies like CpG 1018 to improve vaccine performance. Its contributions are significant to public health, addressing critical needs in infectious disease prevention and cancer immunotherapy.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
405
CEO
Mr. Ryan Spencer
Country
United States
IPO Year
2004
Website
www.dynavax.comDynavax Technologies Corporation (DVAX) Latest News & Analysis
Latest News
Quick Summary
Ciena Corp. will join the S&P 500, replacing Dayforce Inc. Arrowhead Pharmaceuticals will enter the S&P MidCap 400, replacing Ciena, and ADT Inc. will replace Arrowhead in the S&P SmallCap 600, effective Feb. 9.
Why It Matters
Changes in index constituents can impact stock prices and trading volumes, signaling shifts in market perception and investor sentiment regarding these companies.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
On Jan. 15, 2026, 114,000 shares were exercised and sold for about $1.8 million, at an average price of $15.64 per share, executed directly with no intermediaries.
Why It Matters
The sale of 114,000 shares for $1.8 million indicates strong liquidity and investor confidence in the stock, potentially impacting share price and market sentiment.
Source: The Motley Fool
Market Sentiment:
Neutral
Quick Summary
Monteverde & Associates is investigating Dynavax Technologies (NASDAQ: DVAX) following its sale to Sanofi. The firm is noted for recovering millions for shareholders.
Why It Matters
The investigation into Dynavax's sale to Sanofi may signal potential legal issues or shareholder disputes, affecting investor sentiment and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Kahn Swick & Foti, LLC is investigating the proposed sale of Dynavax Technologies Corporation (DVAX) regarding the adequacy of price and process.
Why It Matters
The investigation into Dynavax's proposed sale raises concerns about valuation and process, potentially affecting stock price and investor confidence.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Charles C. Foti, Jr., former Attorney General of Louisiana, has been mentioned in a news release dated December 30, 2025, related to New York and New Orleans. Further context is needed for investor relevance.
Why It Matters
The mention of a former Attorney General could signal potential legal developments or regulatory changes that may impact businesses, influencing investor sentiment and market dynamics.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
The Ademi Firm is investigating DigitalBridge (Nasdaq: DVAX) for potential breaches of fiduciary duty related to its transaction with SoftBank.
Why It Matters
Potential legal issues surrounding DigitalBridge's transaction with SoftBank could impact stock performance, investor confidence, and overall market perception of the company.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About DVAX Stock
What is Dynavax Technologies Corporation's (DVAX) stock forecast for 2026?
Based on our analysis of 10 Wall Street analysts, Dynavax Technologies Corporation (DVAX) has a median price target of $16.00. The highest price target is $16.00 and the lowest is $16.00.
Is DVAX stock a good investment in 2026?
According to current analyst ratings, DVAX has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $15.50. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DVAX stock?
Wall Street analysts predict DVAX stock could reach $16.00 in the next 12 months. This represents a 3.2% increase from the current price of $15.50. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Dynavax Technologies Corporation's business model?
Dynavax Technologies generates revenue by developing and commercializing innovative vaccines, notably its FDA-approved HEPLISAV-B hepatitis B vaccine. The company focuses on utilizing advanced immunology technologies to enhance vaccine efficacy and accessibility, which positions it to capture market share in the biopharmaceutical sector.
What is the highest forecasted price for DVAX Dynavax Technologies Corporation?
The highest price target for DVAX is $16.00 from at , which represents a 3.2% increase from the current price of $15.50.
What is the lowest forecasted price for DVAX Dynavax Technologies Corporation?
The lowest price target for DVAX is $16.00 from at , which represents a 3.2% increase from the current price of $15.50.
What is the overall DVAX consensus from analysts for Dynavax Technologies Corporation?
The overall analyst consensus for DVAX is bullish. Out of 10 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $16.00.
How accurate are DVAX stock price projections?
Stock price projections, including those for Dynavax Technologies Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 19, 2026 3:54 PM UTC